RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Enemem, >>> It's possible that a single compound could reverse neurodegenerative diseases, but unlikely. <<<



Yes, but at .06 cents and running on fumes, we have to cling to any remaining straws that are out there, lol.

I'm skeptical of the prospects of Servier being able to demonstrate a delay in the progression of AD in the first Phase 2. If the trial runs long enough there's a chance, but we don't know what Servier's Phase 2 trial design is. They may only be dosing for 2 or 3 months in this first trial (?), which wouldn't be long enough.

But showing some improvement in cognition/memory after 2 or 3 months seems very possible, even without a BDNF effect. Palliative improvement in AD would still be relatively big news, and would justify longer trials where they could better determine if there is disease modification/BDNF effect.

At this point, Varney can't be too choosy. He needs to partner a low impact program (SA, RD, ADHD) for whatever he can get, and then pray the high impacts work.